What is it about?

This a study detailing an open and enrolling protocol for young adult patient with malignant glioma and diffuse midline glioma. Our study is focused on safety and ability to measure chemotherapy, abemaciclib, within the tumor over time after surgery, all with the purpose of increasing our understanding of disease response.

Featured Image

Why is it important?

This is important because the blood-brain barrier stops good therapy from reaching these aggressive brain tumors and our study is looking at how much drug gets to the tumor as well as for how long and to what regions.


It is an enriching study that will allow patients to become more knowledgeable about their glioma pharmacokinetics and treatment response in real time.

Sadhana Jackson
National Institutes of Health

Read the Original

This page is a summary of: Clinical protocol: Feasibility of evaluating abemaciclib neuropharmacokinetics of diffuse midline glioma using intratumoral microdialysis, PLoS ONE, September 2023, PLOS,
DOI: 10.1371/journal.pone.0291068.
You can read the full text:

Open access logo



The following have contributed to this page